EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids

Jung Hun Kang, Kyung Hee Lee, Seok Jae Huh, Seong-Hoon Shin, Il Hwan Kim, In Gyu Hwang, Dong-Hoe Koo, Dongyun Lee, Su-Jin Koh, Seyoung Seo, Guk Jin Lee, Sang Hoon Chun und 4 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae176 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2024. Verfasst von Jung Hun Kang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju, Korea. Hauptthemen laut MEDLINE: Buprenorphine, Analgesics, Opioid, Transdermal Patch, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center, Ministry of Health & Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The physical dependence on prescription opioids among cancer survivors remains an under-investigated area, with a scarcity of well-designed prospective studies.

Methods

This single-arm, phase-2 clinical trial in Korea assessed the efficacy and safety of a transdermal buprenorphine patch (TBP) in managing physical dependence on prescription opioids in cancer survivors, as confirmed through the DSM-5 criteria or psychiatric consultation for opioid withdrawal. This study involved a 4-phase treatment protocol of screening, induction/stabilization, discontinuation, and monitoring. The primary outcome was the rate of successful opioid discontinuation, as measured by a negative urine-drug screening at 8 weeks. Key secondary outcomes included the resumption of prescribed opioids, changes in both the Clinical Opioid Withdrawal Scale (COWS) and morphine equivalent daily dose (MEDD), and assessments related to the psychological and physiological aspects of dependence and safety.

Results

Thirty-one participants were enrolled. In the intention-to-treat population, the success rate of opioid discontinuation was 58%, with only 2 participants experiencing a resumption of prescribed opioids. Significant reductions were observed in MEDD, which decreased from 98 to 26 mg/day (P < .001), and COWS scores, which decreased from 5.5 to 2.8 (P < .001). Desire to use opioids reduced from 7.0 to 3.0 on a 10-point numeric rating scale (P < .001). Toxicities related to TBP were mild and manageable, without severe precipitated withdrawal symptoms.

Conclusion

TBP may be considered as an alternative therapeutic option in cancer survivors physically dependent on prescription opioids, especially where sublingual formulations are unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineAnalgesics, OpioidTransdermal PatchNeoplasmsSubstance Withdrawal SyndromeHumansFemaleMaleMiddle AgedAdultOpioid-Related DisordersAgedProspective Studies

Stichwörter der Autor:innen

buprenorphinecancer survivorsopioid-related disordersprescription drugssubstance withdrawal syndrome

Substanzen

BuprenorphineAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju, Korea.
  • Department of Hematology-Oncology, Yeungnam University College of Medicine, Daegu, Korea.
  • Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
  • Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
  • Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • Division of Hematology/Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

ORCID-Profile: Se-Il Go

Förderung

  • National Cancer Center
  • Ministry of Health & Welfare, Republic of Korea

Zitieren

APA

Kang, J. H., Lee, K. H., Huh, S. J., Shin, S. H., Kim, I. H., Hwang, I. G., Koo, D. H., Lee, D., Koh, S. J., Seo, S., Lee, G. J., Chun, S. H., Ji, J. H., Oh, S. Y., Choi, J. W., & Go, S. I. (2024). Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids. The Oncologist. https://doi.org/10.1093/oncolo/oyae176

Vancouver

Kang JH, Lee KH, Huh SJ, Shin SH, Kim IH, Hwang IG, et al. Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids. The Oncologist. 2024. doi:10.1093/oncolo/oyae176

BibTeX
@article{Kang2024,
  author = {Kang, Jung Hun and Lee, Kyung Hee and Huh, Seok Jae and Shin, Seong-Hoon and Kim, Il Hwan and Hwang, In Gyu and Koo, Dong-Hoe and Lee, Dongyun and Koh, Su-Jin and Seo, Seyoung and Lee, Guk Jin and Chun, Sang Hoon and Ji, Jun Ho and Oh, Sung Yong and Choi, Jung Woo and Go, Se-Il},
  title = {Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae176}
}
Kostenlos starten →